Your Article Summary
See Latest ArticlesMorphotek, Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer
Morphotek, 06/16/09
Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration cleared its investigational new drug application to study MORAb-004 in the treatment of patients with solid tumors. MORAb-004 targets endosialin, a protein expressed on cells associated with tumors and tumor blood vessel cells.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
Novartis, 11/29/09
Major European regulatory milestone in cardiovascular protection for Micardis : Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Boehringer Ingelheim, 11/29/09
Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/29/09